HUADONG MEDICINE(SZ:000963) Sou Hu Cai Jing·2025-07-13 08:49Group 1 - Obesity is a chronic health condition affecting approximately 270 million people in China as of 2023, leading to increased demand for weight loss medications [1][3] - The Chinese weight loss drug market is estimated to be around 2.1 billion yuan in 2023, indicating significant growth potential due to rising obesity rates and consumer interest [3][5] - Current weight loss drug options in China are limited, and the market is characterized by conservative treatment approaches, prompting companies to invest in this sector [3][7] Group 2 - East China Pharmaceutical Co., Ltd. has developed liraglutide injection (brand name: Lirupin®), approved for treating type 2 diabetes and obesity, with total revenue of 20.965 billion yuan in the first half of 2024 [5] - The rapid advancement of biotechnology and pharmaceutical technologies is expected to enhance the efficacy and safety of weight loss drugs, with a focus on long-acting and multi-target oral medications [7][8] - Research methodologies employed include SCP model, SWOT, PEST, and regression analysis to provide a comprehensive overview of the weight loss drug industry, aiding investment decisions and strategic planning [8]